Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes
Daniel Abate‐Daga, Ken‐ichi Hanada, Jeremy L. Davis, et al.
Blood (2013) Vol. 122, Iss. 8, pp. 1399-1410
Open Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Nikolaos Zacharakis, Harshini Chinnasamy, Mary A. Black, et al.
Nature Medicine (2018) Vol. 24, Iss. 6, pp. 724-730
Open Access | Times Cited: 698
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Marcela V. Maus, Stephan A. Grupp, David Porter, et al.
Blood (2014) Vol. 123, Iss. 17, pp. 2625-2635
Open Access | Times Cited: 585
Current Progress in CAR-T Cell Therapy for Solid Tumors
Shuo Ma, Xinchun Li, Xinyue Wang, et al.
International Journal of Biological Sciences (2019) Vol. 15, Iss. 12, pp. 2548-2560
Open Access | Times Cited: 380
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
Edmund K. Moon, Liang-Chuan Wang, Douglas V. Dolfi, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 16, pp. 4262-4273
Open Access | Times Cited: 376
Prospects for gene-engineered T cell immunotherapy for solid cancers
Christopher A. Klebanoff, Steven A. Rosenberg, Nicholas P. Restifo
Nature Medicine (2016) Vol. 22, Iss. 1, pp. 26-36
Open Access | Times Cited: 332
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong‐Chen Lu, Linda L. Parker, Tangying Lu, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 29, pp. 3322-3329
Open Access | Times Cited: 239
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Rachel A. Burga, Mitchell Thorn, Gary R. Point, et al.
Cancer Immunology Immunotherapy (2015) Vol. 64, Iss. 7, pp. 817-829
Open Access | Times Cited: 200
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 340-340
Open Access | Times Cited: 198
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Yaomei Tian, Daoyuan Xie, Yang Li
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 164
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes
Nikolaos Zacharakis, Lutfi Huq, Samantha J. Seitter, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 16, pp. 1741-1754
Open Access | Times Cited: 124
Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint
Navin Kumar Verma, Brandon Han Siang Wong, Zhi Sheng Poh, et al.
EBioMedicine (2022) Vol. 83, pp. 104216-104216
Open Access | Times Cited: 81
Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function
Chiara Rancan, Marcel Arias-Badia, Pranay Dogra, et al.
Nature Immunology (2023) Vol. 24, Iss. 4, pp. 612-624
Open Access | Times Cited: 45
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results
Maria R. Parkhurst, Stephanie L. Goff, Frank J. Lowery, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2586-2595
Open Access | Times Cited: 20
The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer
Jia Han, B. Zhang, Senyu Zheng, et al.
Cell Transplantation (2024) Vol. 33
Open Access | Times Cited: 17
CAR models: next-generation CAR modifications for enhanced T-cell function
Daniel Abate‐Daga, Marco L. Davila
Molecular Therapy — Oncolytics (2016) Vol. 3, pp. 16014-16014
Open Access | Times Cited: 159
An immunoproteomic approach to characterize the CAR interactome and signalosome
María C. Ramello, Ismahène Benzaïd, Brent M. Kuenzi, et al.
Science Signaling (2019) Vol. 12, Iss. 568
Open Access | Times Cited: 132
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Zachary Roberts, Marc Better, Adrian Bot, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2017) Vol. 59, Iss. 8, pp. 1785-1796
Open Access | Times Cited: 130
The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce, Mohammad Y. Zaidi, Edmund K. Waller, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 117
Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches
Paola Fisicaro, Valeria Barili, Marzia Rossi, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 110
Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy
Sebastian Kobold, Simon Grassmann, Michael Chaloupka, et al.
JNCI Journal of the National Cancer Institute (2015) Vol. 107, Iss. 8
Open Access | Times Cited: 108
Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma
Joal D. Beane, Gary Lee, Zhili Zheng, et al.
Molecular Therapy (2015) Vol. 23, Iss. 8, pp. 1380-1390
Open Access | Times Cited: 102
Prospects for combined use of oncolytic viruses and CAR T-cells
Adam Ajina, John Maher
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 101
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Yong‐Chen Lu, Zhili Zheng, Paul F. Robbins, et al.
Molecular Therapy (2017) Vol. 26, Iss. 2, pp. 379-389
Open Access | Times Cited: 90
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Binglan Zhang, Diyuan Qin, Zeming Mo, et al.
Science China Life Sciences (2016) Vol. 59, Iss. 4, pp. 340-348
Open Access | Times Cited: 88
The Quest for the Best: How TCR Affinity, Avidity, and Functional Avidity Affect TCR-Engineered T-Cell Antitumor Responses
Diana Campillo-Davó, Donovan Flumens, Eva Lion
Cells (2020) Vol. 9, Iss. 7, pp. 1720-1720
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top